Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 10, 2024 22:37 ET | Source: Novotech

Novotech Publishes Research Report on Acute Myeloid Leukaemia Clinical Trial Landscape for Clinical Stage Biotechs

The report presents a comprehensive look at the AML funding landscape, trial density, patient recruitment data
November 22, 2019 01:30 ET | Source: ASLAN PHARMACEUTICALS LIMITED

ASLAN Pharmaceuticals Announces Publication of Preclinical Data on ASLAN003 in AML in Haematologica Journal

SINGAPORE, Nov. 22, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today announced that new preclinical...
March 11, 2019 03:00 ET | Source: ASLAN Pharmaceuticals Limited

ASLAN Pharmaceuticals Signs New Agreement With Biogenetics for Commercialisation of ASLAN003 in South Korea

SINGAPORE, March 11, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology-focused biopharmaceutical company developing novel therapeutics for global...
January 04, 2019 02:00 ET | Source: ASLAN Pharmaceuticals Limited

ASLAN Pharmaceuticals Announces IND Submission for ASLAN003 to U.S. FDA and Conclusion of 30-Day Review Period

- ASLAN003 is an orally active, potent inhibitor of DHODH that has the potential to be first-in-class in AML- Positive interim Phase 2a data for ASLAN003 in AML was presented at the 2018 ASH Annual...
August 20, 2018 02:49 ET | Source: ASLAN Pharmaceuticals Limited

ASLAN Pharmaceuticals Granted Orphan Drug Designation by the FDA for ASLAN003 for the Treatment of Acute Myeloid Leukaemia

SINGAPORE, Aug. 20, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and...